1. 28. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO™) in Participants by Age, Sex, and Baseline GP-ELISA Titer: A Post Hoc Analysis of Three Phase 2/3 Trials. (31st December 2020) Authors: Simon, Jakub; Kennedy, Stephen; Mahon, Barbara; Dubey, Sheri; Grant-Klein, Rebecca; Liu, Ken; Hartzel, Jonathan; Coller, Beth-Ann; Welebob, Carolee; Hanson, Mary; Grais, Rebecca Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials. Issue 46 (2nd November 2022) Authors: Simon, Jakub K.; Kennedy, Stephen B.; Mahon, Barbara E.; Dubey, Sheri A.; Grant-Klein, Rebecca J.; Liu, Ken; Hartzel, Jonathan; Coller, Beth-Ann G.; Welebob, Carolee; Hanson, Mary E.; Grais, Rebecca F. Journal: Vaccine Issue: Volume 40:Issue 46(2022) Page Start: 6599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗